What Ellansé is
Not every Ellansé lump is the same thing
| What it may be | What it can relate to |
|---|---|
| Early, non-inflammatory deposit | Product concentration, a bolus, placement too superficial, or a large volume in one area. The Ellansé recommendations link nodules of this kind mainly to technique.1 |
| Firm area or fibrosis | A thickened area rather than a distinct lump, sometimes reflecting the collagen response itself. |
| Delayed inflammatory nodule | An immune-mediated reaction appearing weeks or months later, not necessarily linked to how the product was injected. |
| Foreign-body granuloma | Granulomas after PCL filler have been reported, including late-onset cases.2,3 This is a specific diagnosis, not another word for a lump. |
| Infection | Pain, heat, redness or discharge. This has to be considered before anything anti-inflammatory is injected. |
| Something that does not fit | An unusual appearance, behaviour or timing, which may need further investigation. |
Before I inject anything, I want to know what I am treating
When ultrasound is not enough
How I manage Ellansé lumps
Why I do not automatically inject steroid into every Ellansé lump
Ellansé in the nose
How I try to reduce the risk
- Volume. My personal practice is a maximum of 2 ml of Ellansé in one session. This is my own limit, not an Ellansé guideline.
- Small amounts. I place small amounts at a limited number of structural points, usually following an eight-point approach, rather than larger boluses. The Ellansé recommendations also advise small, gradual amounts and avoiding overcorrection.1
- Even delivery. With a cannula, product can build up and be released in one larger amount; I take care to deliver it evenly.
- Caution in the jawline and chin, where larger amounts are often used and where I see deposits most often.
Lump after Ellansé?
When to get urgent help
Frequently asked questions
Not with hyaluronidase, which only breaks down hyaluronic acid. Collagenase has been described for selected Ellansé nodules in a small case series,6 but it is not a universal dissolver. Management depends on what the lump actually is.
No. It can be a non-inflammatory deposit of product, a firm or fibrotic area, a delayed inflammatory nodule, a true foreign-body granuloma, or occasionally infection. Ultrasound helps tell these apart.
Not necessarily. Some lumps relate to volume and placement, but delayed inflammatory nodules and granulomas can occur even when the injection was done well.
Some small, non-inflammatory lumps soften over time. Others persist while the product is present, which depends on the version used. A scan helps decide whether to wait, treat or investigate further.
Not automatically. Steroid can be appropriate in selected inflammatory lesions, but it can thin the skin and the fat beneath it, so I decide only after examining and scanning the area.
My personal practice is a maximum of 2 ml in one session. This is my own limit, not an official guideline.
Yes. You do not need to have been my patient before.
Diagnose first, then decide.
References
2. Chiang C, Peng J, Peng H. Filler-induced granuloma from polycaprolactone-based collagen stimulator injection in the tear trough area: a case report. J Cosmet Dermatol. 2021;20(5):1529-1531. doi:10.1111/jocd.14010
3. Hong J, Sun B, Shin S, Kim B. Late-onset filler-induced granuloma after polycaprolactone-based filler treated with high-intensity focused ultrasound and quantum molecular resonance technology. Dermatol Surg. 2022;48(6):693-694. doi:10.1097/DSS.0000000000003424
4. Wu et al. Point-of-care ultrasound (POCUS) for precision management in Ellanse-treated patients. J Cosmet Dermatol. 2025;24(6):e70262. doi:10.1111/jocd.70262
5. Shekarriz P, Shojaee P. Ultrasound-assisted management of filler-related complications: report of a successful treatment of delayed-onset nodules related to polycaprolactone-based filler. Clin Case Rep. 2022;10(11):e6646. doi:10.1002/ccr3.6646
6. Wu et al. iCare technique of dissolving Ellanse M nodules using collagenase: a case series and experimental study. J Cosmet Dermatol. 2025;24(5):e70201. doi:10.1111/jocd.70201
7. Flores Rodríguez JC, Porras Zamora BM, Rico Macías NM, et al. The management of poly-L-lactic acid (PLLA) nodules: a scoping review and evidence-mapped clinical pathway. Cureus. 2026;18(6):e110742. doi:10.7759/cureus.110742
8. Weinhammer A, Shields B, Keenan T. Intralesional corticosteroid-induced hypopigmentation and atrophy. Dermatol Online J. 2020;26(1). doi:10.5070/d3261047199